Research Article
Lester Raymundo Dominguez Huarcaya
Lester Raymundo Dominguez Huarcaya
Corresponding Author
Institute
of Clinical Research, Faculty of Medicine, National University of San Marcos.
Lima Peru.
And
Laboratory
of Pharmacology, Faculty of Medicine, National University of San Marcos. Lima
Peru.
E
mail: ldhlester@gmail.com
Jorge Luis Arroyo Acevedo
Jorge Luis Arroyo Acevedo
Institute
of Clinical Research, Faculty of Medicine, National University of San Marcos.
Lima, Peru.
And
Laboratory
of Pharmacology, Faculty of Medicine, National University of San Marcos. Lima,
Peru.
E
mail: jarroyoa@unmsm.edu.pe
María Fernanda Dominguez Ríos
María Fernanda Dominguez Ríos
Pre
graduate Student of the Faculty of Psychology. Pontificia Universidad Católica
del Peru, Peru.
E-mail: mfdominguezrlince@gmail.com
Abstract
Gynerium sagittatum (Caña Brava) is used in ethnomedicine to treat
benign prostatic hyperplasia without any scientific information on its safety
profile after its administration. Evaluate the possible curative effect of
methanolic extract of Gynerium sagittatum (GS) on testosterone-induced benign
prostatic hyperplasia in rats. 36 male rats with an average weight of 300 g ±
50 g and 2.5 months of age were used, 6 random groups of 6 rats each were
formed; Group I, blank: with physiological serum 2 mL / Kg every 24 h. for Per
Orally (PO), control group II: with olive oil subcutaneous 0.5 mL +
testosterone 25 mg (TA), group III: with olive oil subcutaneous 0.5 ml +
testosterone 25 mg + extract of Gynerium sagittatum 50 mg/kg PO, group
IV: olive oil subcutaneous 0.5 mL + testosterone 25 mg + extract of Gynerium
sagittatum 250 mg/kg, Group V: olive oil subcutaneous 0.5 mL + testosterone
25 mg + extract of Gynerium sagittatum 500 mg/kg, Group VI: olive oil
subcutaneous 0.5 mL + testosterone 25 mg + Finasteride 0.6 mg/kg. weighed
subsequent treatments, and prostate, kidneys, and liver were measured, and a
pathological study determined prostate-specific antigen and serum determination of toxicity markers
by liver profile. A 99% decrease in the comparative prostate index was observed
in control group I, and a better effect was observed at a dose of 500 mg/kg (P
<0.004). This study has shown that GS has a beneficial effect on induced
benign prostatic hyperplasia in rats.
Abstract Keywords
Prostate, specific
antigen toxicity, flavonoids, Gynerium sagittatum.
1.
Introduction
Benign
prostatic hyperplasia (BPH) is the most common benign neoplasm of aging men and is present in approximately 8% of men in the
fourth decade of life but up to 90% of men in the ninth decade [1]. Hyperplasia is observed globally in almost 50 percent
of patients aged 60 years and 90 percent of patients aged 80 years and under
30, respectively. Population studies indicate that from the age of 40, common
uropathy symptoms secondary to benign prostatic hyperplasia differ from 13% and
exceed 60% in older patients. Let us consider that with age, the incidence of
lower urinary tract symptoms (LUTS) increases. The population is aging in most
European countries, and the number of men seeking medical attention for
LUTS/BPH will rise dramatically over the next 20 years [2]. Mortality due to BPH is low, and patient's quality of
life is conditioned by its evolutionary attitudes, evolutionary attitude, and
the formation of evacuation symptoms with varying severity effects on the
patients of life on the patient's quality of life. The prevalence of
histological BPH is estimated to occur in 8% of men aged 31 to 40 years, up to
50 % of men aged 51 to 60 years, and more than 80% of men. It is more than 80
years of age and it is uncommon among young men. Symptoms are measured using
scales of symptom scoring.
Approximately
80% of those over 50 have BPH in a greater or lesser degree, so 33% of those
over 50 have a well-formed adenoma already. Ninety-five percent have BPH at 80
years of age. The possibility that an 80-year-old man wants prostate surgery
has been reported to be 30 percent [3]. We can see from other foreign sources that the
anatomical or histological evidence of BPH present in autopsy studies has been
estimated at 50 to 60 years (40%), 60 to 70 years (60%), and 70 to 80 years
(80%) [4].
The
disorder becomes a clinical entity linked to subjective symptoms, with lower
urinary tract symptoms being the most common manifestation. However, it must be believed that not all men
with BPH histology will develop severe LUTS, while LUTS will develop in other
men who do not have BPH histology. The incidence of symptoms and signs of BPH
in men may be associated with other prostate disorders. It may be a risk factor
for the development of prostatitis or prostate cancer, other causes of sub-ventricular
obstruction (urethra), stenosis, bladder neck sclerosis, bladder conditions (in
situ carcinoma, inflammation, stones, or other conditions leading to a
non-specific disease like lower urinary tract infections. Another critical
factor is state propensity to expand [5, 6]. The pharmacological options that we currently have are
the following:
• Alpha-adrenergic receptor blockers
• 5-alpha
reductase inhibitor
• Inhibitor
of the enzyme phosphodiesterase 5
•
Anticholinergic agents
However,
the ever-increasing interest in flavonoid-based natural products increases
interest in flavonoid-based natural products due to the recognition of their
broad pharmacological activity. Due to this fact, pathologies such as diabetes
mellitus, cancer, heart disease, viral infections, and stomach protective
effects have been identified like ulcer duodenal, and inflammatory diseases.
Other activities that should be highlighted include their antiviral and anti-allergic
properties and their anti-thrombotic and anti-inflammatory properties [7]. According to the available evidence, extracts from
various plants used in the treatment of BPH have a mild beneficial effect, like
that of a placebo, to improve symptoms and urinary flow measurements. However,
it will be essential to have sufficient length and good design studies to
determine its role in the disease's progression and minimize complications. We
chose the ethanolic extract for the pharmacological properties that it offers
us at the time of carrying out the phytochemical march, which provides us with
obtaining better results in the presence of various molecules. At the moment
there are no previous studies for this plant where the ethanolic extract has
been carried out or obtained to carry out other studies. It is the first time
that this procedure is being carried out for said plant.
The 5-alpha-reductase
inhibitors represented: finasteride and dutasteride; finasteride is a selective
inhibitor of the type II isoenzyme, and dutasteride, a non-selective inhibitor
of type I and II isoenzymes, have relevant adverse effects such as decreased
libido, erectile dysfunction and ejaculation disorders, gynecomastia. Combined
alpha-blocker therapy with 5-alpha reductase inhibitors is an effective method,
care must be taken in treatment lasting less than a year due to suspicion of
intravesical obstruction and high residual urine volume [8]. Currently, there is a growing interest in flavonoids
because they present a broad pharmacological activity, possibly a consequence
of their antioxidant capacity. Due to this fact, there have been described
protective effects in pathologies such as cancer and inflammations, viral
infections, ulcers, stomach, duodenal, and heart disease. The components of the
root of Gynerium sagittatum would inhibit the enzymatic process that
converts testosterone to DHT, which is the main androgen responsible for stimulating
prostate growth. That is the aqueous extract of the root of the "caña
brava" decreases the DHT concentration in the prostate and decrease of the
tumor of the prostate [9,10].
The pathophysiological evolution of BPH occurs with processes of an inflammatory or infectious nature that affect the prostate gland; in addition, the inflammation process can independently affect the development of BPH [11]. In different countries of the world and in Peru, specifically, there are medicinal plants that contain flavonoids, tannins, which show an anti-inflammatory and antioxidant effects. This is the case of Moringa oleifera, whose leaves and roots have shown a greater antioxidant and anti-inflammatory effect than the seeds [12,13]. On the other hand, phytochemical knowledge of the Gynerium sagittatum (caña brava) species is not well described. Thus, more studies are necessary to validate its traditional use. In this context, we have evaluated the possible curative effect of the methanolic extract of Gynerium sagittatum on induced BPH by testosterone in rats. Considering the magnitude of the problem, this research aims to contribute to the therapy of BPH to be able to take it into account in the future, which will help reduce costs, giving an alternative to conventional drugs which have a high price. The justification of the study is based on the analysis of a qualitative phytochemical march, since we do not have the technology to carry out a quantitative phytochemical march. However, our study is based on qualitative results with the results of the presence of substances such as flavonoids, alkaloids, etc; which allows us to analyze the study and give theoretical support to its results.
2.
Materials and methods
The guide for the Gynerium sagittatum (caña brava)
plant was sent to the Natural History Museum of the National University of San
Marcos for its taxonomic study, Constancy N ° 12-USM-2018.
2.2 Animals
Adult Holtzman rats were obtained from our Animal
House at the National Institute of Health and used for the present study. Rats
were kept 6 per cage at room temperature (22 °C) with a 12:12 hr light / dark
cycle. They have also fed them Purina laboratory food and tap water ad libitum.
The "Guide performed all animal experiments for the Care and Use of
Laboratory Animals" of the US National Institutes of Health, 08. The
Institutional Review Board of the Office of Scientific Research of the
“Universidad Nacional Mayor de San Marcos” approved the study.
2.3 Preparation of aqueous ethanol extract of Gynerium sagittatum (Caña Brava)
The plant guide was dried in the sun within the
temperature range of 30–42 °C for five days before being reduced in size
to a coarse powder with an electric grinder. The uncultivated plant powder
weighing 1000 g was extracted with 90% aqueous ethanol in three cycles using a
Soxhlet extractor. The crude extract was filtered with Whatman No. 4 filter
paper and the filtrate was concentrated in vacuo at 30 °C to obtain 80 g of the
residue's weight (8.7% w/w). The residue was stored in an airtight bottle and kept in a refrigerator at 4 °C until use.
2.4 Phytochemistry of Gynerium sagittatum (Caña Brava)
For this procedure, the methanol extract was dissolved
in physiological saline solution, separated, and reserved to carry out the
phytochemical march. The sample had a content of 5 mg of the section that was
dissolved in physiological serum at volumes of 3 to 5 ml in tubes and test 8 of 5 mL. The phytochemical examination of the aqueous
extract of Gynerium sagittatum (Caña Brava) was carried out using
standard phytochemical procedures, 9, 10, 11, 12, and 13. The aqueous extract
of Gynerium sagittatum (Caña Brava) was lyophilized before the extraction
procedures. After extraction in methanol, the presence of flavonoids (Shinoda
test), anthraquinones (Bornträger reaction), tannins (gelatin / ferric chloride
test), phenolic compounds (ferric hydroxylate test), free amino acids (trial of
ninhydrin), and glycosides (Polish test) were evaluated, [14-17].
2.5 Benign prostatic hyperplasia induction
Two weeks before the start of therapy, BPH induction
was performed. The model was induced by subcutaneous injection of testosterone
enanthate twice at a dosage of 25 mg (0.1 mL, 250 mg / 1 mL presentation) on
day one and day 7; this procedure was performed daily in all rats (Wang R,
2015). Testosterone enanthate, diluted in 0.5 ml of extra virgin olive oil for
home use (this oil olive was chosen for the experience with other studies in
our Pharmacological department and also we do not have oil olive
pharmacological), was prepared at a dosage of 25 mg (0.1 mL). Being prepared
corresponds to the benign prostatic hyperplasia caused by the agent for the groups II, III, IV, V, and VI from
the experimental study. Experimental groups III, IV, and V were administered
daily: testosterone enanthate in 25 mg of oil solution subcutaneously plus the
methanolic extract of the Gynerium
sagittatum (caña brava) guide prepared as mentioned above, in the following
doses: 50 mg/ kg, 250 mg/kg and 500 mg/kg orally for 30 days, this was done
with a metallic orographic cannula.
The experimental group VI was administered
testosterone enanthate in 25 mg oil solution subcutaneously plus 0.6 mg/kg of
finasteride; this was used as a comparator for the treatment with the extract
of Gynerium sagittatum (caña brava), [18]. It should be noted that a pilot study was carried out
before the start of the trial, with two rats per group, which allowed the
administration of the times and the adjustment of the administration and
induction techniques of the disease in the animals.
2.6 Experimental design
Male rats with a mean weight of 300 g ± 50 grand and a
mean age of 2.5 months, randomly distributed into six groups of 6 animals each,
were selected for this research. At Bioterium, they were conditioned for seven
days. Faculty of Human Medicine, National University of San Marcos; 6 metal
cages with animal capacity were then housed. It was set at a temperature
between 19 °C- 22 °C, 40-50 percent humidity, with alternating 12-hour light/
dark cycles starting at 8 a.m. Water and a nutritious diet were given to them
ad libitum. The experimental groups are described below
a) White group (I): with physiological saline 2 mL/kg
every 24 hours orally for 30 days.
b)
Control group (II): with 0.5 mL subcutaneous olive oil + 25 mg of
testosterone (TA) for 30 days.
c)
Experimental group (III): extract of TA + Gynerium sagittatum (caña
brava) 50 mg/kg orally for 30 days.
d)
Experimental group (IV): extract of TA + Gynerium sagittatum (cane
brava) 250 mg/ kg orally for 30 days.
e)
Experimental group (V): extract of TA + Gynerium sagittatum (caña
brava) 500 mg / kg orally for 30 days.
f) Experimental group (VI): TA + Finasteride 0.6 mg / Kg
orally for 30 days.
2.7 Method of obtaining blood samples and extraction
of the prostate, kidney, and liver glands.
On day 31, with an overdose of 100 mg/kg sodium
pentobarbital, animals in all research groups were euthanized. By intracardiac
puncture with a 21G needle, approximately 5 ml of blood was drawn from each of
the rats after expiration; the blood was then deposited into labeled test tubes
(5 ml) containing 0.01 mL of 100 mg / 5 mL sodium heparin. Both samples were
immediately moved to “Dos de Mayo Hospital” biochemical analysis laboratory
calculation. The measure often calculated total prostate-specific antigen
(serum PSA), urea, TPG, alkaline phosphatase, total bilirubin and was analyzed
according to the institution's methodology.
The prostate glands were surgically removed from each
of the animals after blood collection and fixed with 10 percent formaldehyde.
The following measurements were taken for each of the prostate glands and with
the regular forceps clamp holder: Length (ventral length), width, and height.
• Weight in grams, using a high precision analytical balance, with a sensitivity of 0.1 mg. All measurements were recorded on some cards created to collect this information.
Kidneys and liver were removed from each of the rats
for histopathological evaluation. We sent the samples for the
anatomopathological study of the tissues designed for tiny review: also
comparative method was used with the tissue samples of the rats of the control
group (White group). The pathological study was performed with a
high-resolution Nikon binocular microscope (40x magnification) with built-in
light, which allows the review of morphological alterations in tissues and
cells.
2.8 Histopathological examination
The prostate samples from the rats were set for 24
hours with Bouin's fixative. The samples were dehydrated, rinsed with xylene,
and embedded in paraffin using graduated alcohols. Hematoxylin and eosin were
produced in six-micron thick sections and stained with (H&E). Using a light
microscope, histological observation was prepared (Olympus BX41). The magnitude
of the prostate histopathological changes was measured, while the glandular
cavity diameter and height of the glandular epithelium were measured.
The prostate anatomy pathology research was also
conducted at the macroscopic level: it was performed by measuring prostate
measurements (length, width, and height) compared to the white group (I). It
was considered that when the prostate was found to be smaller than that of the
target group's experimental animals or the like, there was a curative effect.
2.9 Determination of the prostate index (PI)
PI was calculated from the ratio of prostate weight
(PW) to body weight (BW) of each rat as follows: % inhibition = 100 - [(normal
/ negative treatment control - normal control) x 100].
2.10
Statistical analysis
The SPSS version 21 statistical package for Windows
was used to conduct all statistical analyses; the data will be interpreted as
an average ± standard deviation at a confidence level of 95 percent; variable
tests will be analyzed by ANOVA, and a p-value <0.05 will be considered
relevant compared to Dunnett's C. Multiple comparison comparisons will be
evaluated by ANOVA using Fisher's LSD test, and a p-value <0.05 will be
considered suitable appropriate compared to Dunnett's C.
3. Results and discussion
3.1 Phytochemistry of Gynerium sagittatum (Caña Brava)
The Gynerium sagittatum (Caña Brava) guide
methanolic extract has an extraction yield of 50 percent by weight. Its
organoleptic features include its brown, crystallizable, and hygroscopic, oily
appearance. Qualitative phytochemical research showed that the methanolic
extract contains abundant free amino acids, phenolic compounds, glycosides, and
anthraquinones in the Gynerium sagittatum guide (Table 1).
Table 1. Results of the phytochemical march of Gynerium sagittatum (cane brava)
Metabolite |
Reagent |
Results |
Tannins |
Jelly |
- |
Phenolic
compounds |
Ferric
chloride |
++ |
Free
Amino Acids |
Ninhydrin
reaction |
+++ |
Alkaloids |
Dragendorff
reaction |
- |
Glycosides |
Mayer's
reaction |
- |
Anthraquinones |
NaOH |
++ |
Flavonoids |
Shinoda
reaction |
++++ |
The secondary compound identification tests have
detected free amino acids, phenolic compounds, glycosides, anthraquinones,
and flavonoids. Absent (-), Little quantity (+), Regular quantity (++),
Abundant quantity (+++) |
3.2 Evaluation of serum PSA levels associated with
the curative effect of the methanolic extract of Gynerium sagittatum (caña brava) guide.
Effects of serum PSA levels when determining the
curative effect of the methanol extract according to the recommendations of Gynerium
sagittatum (Caña Brava) indicate a higher decrease in serum PSA values with
an extract dose of 500 mg/kg compared to the second extract dose and compared
to finasteride above the 3-dose guidance methanol extract results. (Fig. 1 & 2).
Figure 1. Comparison to evaluate the volume of the prostate
gland when assessing the beneficial effect of the methanolic extract of Gynerium sagittatum (wild cane) in
benign prostatic hyperplasia induced in rats. Values are mean ± SD (n = 6);
mean values within the same column with different lowercase superscripts are
significantly different (P <0.05) according to Duncan's multiple range test
to evaluate the with ANOVA technique. SD = standard deviation.
Figure 2. Comparison to evaluate the results of urea, TGP, FA,
and BT when assessing the beneficial effect of the methanolic extract of Gynerium sagittatum (caña brava) in
benign prostatic hyperplasia induced in rats. Values are mean ± SD (n = 6); mean values within the
same column with different lowercase superscripts are significantly different
(P <0.05) according to Duncan's multiple range test to evaluate with the
ANOVA technique. SD = standard deviation.
3.3 Evaluation of the prostate index
The findings of the Prostate Index assessment of the
curative effect of the methanol extract of the Gynerium sagittatum (caña
brava) guide show a reduction of the PI with the extract dose to 500 mg/kg
(p<0.004) relative to other extract doses and compared to finasteride, which
is below 500 mg/kg dose of the Gynerium
sagittatum extract methanol (Fig. 3).
Figure 3. PSA level evaluates the curative effect of the
methanolic extract of the Gynerium
sagittatum (wild cane) guidelines in benign prostatic hyperplasia in rats. Statistical
analysis: the test of multiple comparisons using the Tukey test shows that
p<0.0001. We can identify that Average PSA
decreases with the extract of the Gynerium
sagittatum at 250 mg/kg
3.4 Evaluation of the dimensions of the prostate.
The measurement of prostate gland measurements
indicated a decrease in prostate gland dimension with an extract dosage of 50
mg/kg when assessing the curative effect of the methanolic extract of the Gynerium
sagittatum (caña brava) guide. There is also evidence of a drop in prostate
and height with a 250 mg/kg dose of the extract (Fig. 4).
Figure 4. Prostate index evaluated the beneficial effect of the
methanolic extract of the Gynerium sagittatum
(caña brava) guidelines in benign prostatic hyperplasia in rats. Statistical
analysis: the test of multiple comparisons using the Tukey test shows that
p<0.051. We can identify that the Average Prostate index decrease with the
extract of the Gynerium sagittatum at
250 mg/kg.
3.5 Evaluation of the volume of the prostate gland.
The findings of the assessment of the prostate gland
volume when assessing the curative effect of the methanol extract indicated in
the Gynerium sagittatum (caña brava) guide shows a decrease in the
prostate gland volume with an extract dose of 250 mg/kg compared to the other
extract doses and compared to the finasteride dose of less than 500 mg/kg of
the methanol extract of Gynerium sagittatum.
3.6 Evaluation of the weight of the prostate.
The findings of the prostate gland weight assessment
when measuring the curative effect of the methanol extract of the Gynerium
sagittatum (caña brava) guide indicate a similar decrease with the extract
dose of 250 mg/kg, accompanied by doses of 50 mg/kg, respectively (See Table
3).
3.7 Weekly assessment of body weight.
The findings of the weekly body weight evaluation
during the 30 days of the trial to test the curative effect of the Gynerium
sagittatum (caña brava) methanol extract recommendations indicated a
reduction in the dosage of 500 mg/kg extract relative to the other doses of the
extract and compared to finasteride, which is higher than the results of the
three doses of methanol extract. Such findings agree with the bodyweight averages (Fig. 5).
Figure 5. dimensions of the prostate gland when evaluating the
curative effect of the methanolic extract of Gynerium sagittatum (wild cane)
guidelines in benign prostatic hyperplasia in rats. Statistical
analysis: the test of multiple comparisons using the Tukey test shows that
p<0.001. We can identify that the average of long, comprehensive, and high
decrease of the extract of Gynerium
sagittatum at 250 mg/kg
3.8 Evaluation of serum biochemical analyses of
urea, TGP, FA, and BT.
The findings of the biochemical analysis evaluation to
evaluate the serum levels of urea, TGP, FA, and BT when assessing the curative
effect of the Gynerium sagittatum (caña brava) methanol extract is as
follows: urea (mean value: 17 - 42 mg/dL) shows values within the normal range
but with a better outcome at the 250 mg/kg extract dose; TGP (mean value: 17 -
42 mg/dL) shows values within the normal range but with a better outcome at the
250 mg/kg extract dose (Fig. 6).
Figure 6. weekly body weight when evaluating the curative
effect of the methanolic extract of the Gynerium
sagittatum (wild cane) guidelines in benign prostatic hyperplasia in rats.
Statistical analysis: the test of multiple comparisons using the Tukey test
shows that p<0.243. We can identify that the effect curative evaluating the
weekly bodyweight decrease with the extract A of Gynerium sagittatum at
50 mg/kg.
3.9 Effect of the extract on the histopathology of
prostate tissue.
The findings of microscopic (pathological)
observations of histological parts of the prostate gland in all experimental
groups show the following: 500 mg/kg oral extract of Gynerium sagittatum
(Caña Brava) if it has a curative effect in rat-induced benign prostatic
hyperplasia (Fig. 7 B). The findings of microscopic analyses of the
histological parts of the liver in all experimental groups indicate that no
cellular alterations and histopathological alterations related to the toxicity
of the extract and comparators have been found, indicating the safety of
treatment with Gynerium sagittatum (caña brava) extract at the level of
the liver. The findings of microscopic (pathological) studies of the
histological parts of the kidney indicate cellular congestion with 500 mg/kg of
Gynerium sagittatum extract (Caña Brava) and 0.6 mg/kg of finasteride,
suggesting that there is no evidence of cellular toxicity in the 50 and 25
mg/kg doses of Gynerium sagittatum extract (Caña Brava) experimental
classes (Fig. 7 A, B, C, D, E). It is noted that the vascular contours of the acini and
muscle fibers are still formed in Experimental Group V (40X). A 500 mg/kg
extract of Gynerium sagittatum (Caña Brava) was orally administered.
Figure 7. A- Liver without histological alterations (40X). B-
Liver without histological alterations (40X). Gynerium sagittatum (Caña
Brava) extract 50 mg/kg was orally administered. C- Liver without
significant histological alterations (40X). Gynerium sagittatum (wild cane)
extract was administered orally, 250 mg/kg extract. D- Kidney with euro typic
standard histological structure (40X). Gynerium sagittatum (wild cane)
extract 50 mg/kg was orally administered. E- Kidney with a preserved
histological system (40X). Gynerium sagittatum (wild cane) extract was
administered orally, 250 mg/kg extract.
The antecedents of the conventional usage of the Gynerium
sagittatum (Caña Brava) guide suggest the use in the form of oral infusion [19]. However, because of the partial polarity of the
methanol solvent before chains of different lengths and contradictions of the
solutes, because of the partial polarity of the methanol solvent before chains
of various sizes and polarities of the solutes, a higher extraction coverage of
all the substances and beneficial metabolites of the plant was suggested for
this examination, resulting in a robust carrying capacity of the metabolites
linked to the content.
The presence of phenolic compounds, free amino acids,
glycosides, anthraquinones, and flavonoids detected by the phytochemical march
of the methanolic extract, which agrees with the findings of researchers [19, 20], who also identified these compounds, as well as new
phenolic compounds ((2R, 3R)-2,3-trans-7, 40-dimethoxy-dihydro flavanol, (2R,
3S, 4S)-2,3-trans-3,4-cis-7,40-dimethoxy-3,4-dimethoxy-3,4-flavandi). All these
plant metabolites have been used as an anti-inflammatory, analgesic, and
diuretic treatments in the Peruvian Amazon. In comparison, asthma and anemia
were treated with leaf infusion. Therefore, the process used in this trial to
induce the benign prostatic hyperplasia model is that it increases serum
testosterone levels that produce an exclusively exogenous induction of benign
prostatic hyperplasia, [20,21], which indicates that the same effect occurs
molecularly. By disease induction, this description shows us the precise and
scientific effect of the production of exclusively exogenously induced benign
prostatic hyperplasia, at the end the disease's process was also demonstrated
once again [21].
According to a study conducted with plants with a high
percentage of flavonoid content and using high-performance liquid
chromatography (HPLC), it was found that the flavonoids present in the vast
majority of plants with the presence of flavonoids have the substances baicalin
and gentiopicroside that provide phytotherapy treatment that acts on BPH-1
cells and has been found to suppress cell viability As far as their mechanisms
are concerned, they inhibit cell growth by decreasing endogenous cyclin D1 protein
levels and preventing the S step during the progression of the cell cycle. The flavonoid treatment of BPH-1 cells
suppressed the development of prostaglandin E2 and protein levels of
cyclooxygenase-2 (COX-2). Secretion of proinflammatory cytokines, interleukin-8
and interleukin-6; this hypothesis of action is also applied to the findings of
the assessment of prostate gland measurements (Fig. 4) in the evaluation of the beneficial impact of the
methanol extract of the Gynerium
sagittatum (caña brava) guidelines, showing a decrease in prostate gland
dimension with a dose of Gynerium
sagittatum. There is also evidence of reducing prostate gland with and
height at the dosage of 250 mg/kg of the extract [23].
The results of the assessment of the prostate index,
the volume, and weight of the prostate gland (Fig. 7) indicate a decrease in the extract dose at 250 mg/kg when
assessing the beneficial effect of the methanolic extract of the Gynerium sagittatum (caña brava) guide;
this effect may be due to the inhibitory effect of 5 alpha-reductase, a
suggestion that leads us to the guide utilization of the extract. Significant
inhibition of Type I and Type II 5 alpha-reductase was demonstrated in a
specially formulated 5-day model of co-cultured human prostate cell therapy
with 10 mg/mL of permixon (a plant containing flavonoids as the study extract
in this trial) [23, 24].
A decrease in the amount of the extract to 500 mg/kg
compared to the other doses of the extract and other differences with
finasteride mentioned above when evaluating the weekly body weight during the
30-day trial. The results of the three doses of the Gynerium sagittatum
(caña brava) methanolic extract guide also showed a gradual increase in
weekly body weight in the group that induces benign prostatic hyperplasia in
rats. These findings agree with bodyweight averages. The mechanism by which
this outcome occurs is that testosterone acts with an anabolic effect and acts
on the genes that activate growth factors, stimuli of actin, and myosin, and
culminates in an increase in muscle mass, increasing by increasing body weight [23-25].
Based on the results obtained from the evaluation of
the biochemical analysis to determine the serum levels of urea, TGP, FA, and
BT, it is shown that extract of GS does
not produce any toxicity in the organs producing these markers, such as the
liver and kidney when evaluating the beneficial effect of the methanolic
extract on the Gynerium sagittatum (Caña Brava) guide. Overall,
flavonoids are considered good scavengers of free radicals. To investigate the
effect of xenobiotics and phytochemicals (flavonoids) on medicine, the liver is
an essential functional model. For which this research looks especially
promising. They inhibit the detoxification of CYP450 pathways when flavonoids
are present and prevent harmful components' metabolism, including
tetrachloride, paracetamol, and thioacetamide. The study of plant-derived
flavonoids as detoxifying agents should encourage this evidence. Through the
antioxidant/electrophile response element (ARE/EPRE) in the promoter domain,
polyphenols could activate the detoxification enzyme [24, 25].
In this study, glandular proliferation with altered fiber-muscular
stoma and without matrix complications was demonstrated by control group
histopathology. However, a contrast was observed at a dose of 500 mg/kg orally
after thirty days of treatment with Gynerium sagittatum (Caña Brava)
extract when it had a curative effect on rat-induced benign prostatic
hyperplasia. Although therapeutic agents' mechanisms for BPH treatment have
been reported, antioxidant/free radical imbalance or oxidative stress is
postulated to be a critical, crucial essential factor in BPH development and
the overproduction of process species reactive oxygen. The cause of oxidative
stress contributing to tissue damage and the pathogenesis of diseases related
to oxidation is inflammation. The section seems to have had its curative effect on benign prostatic
hyperplasia; other researchers' studies confirmed this information [23, 25, 26].
The methanol extract of the Gynerium sagittatum
(caña brava) guide shows, in Figure 6, a more significant decrease in serum
PSA values with an extract dose of 500 mg/kg, as shown in other studies where
flavonoids may inhibit the production of PSA, including isoflavones (genistein,
biochanin A), flavones (luteolin, chrysin) and flavonoids (naringenin), which
may hinder the production of PSA. Not well studied is the ability of flavonoids
and other polyphenols to regulate androgenic effects. The various mechanisms
through which these compounds inhibit PSA and other androgen-regulated proteins
have been demonstrated by those studies. In the presence of resveratrol,
androgen-induced decreases in PSA and human glandular kallikrein (hK2)
production. Similar outcomes were seen with polyphenols from green tea (GTP).
It was found that before treatment with testosterone, 20-60 mg/ml of GTP
incubated with LNCaP cells significantly reduces the production of ornithine
decarboxylase, another androgen-regulated protein leading to the production of
PSA [27].
One of the most common urological disorders affecting
older men is benign prostatic hyperplasia (BPH). It is non-cancerous prostate
gland hyperplasia caused by the urethra-surrounding epithelial and stromal cell
tissue of the prostate that obstructs urine flow. Although there is no clear
evidence for the pathogenesis of BPH, significant critical factors related to
the development and progression of BPH appear to be aging and testicular
androgens. The prevalence of BPH is found in 50 percent of men at 60 and more
than 80 percent of men older than 80. Androgen-dependent growth of the prostate
[6].
The 5-alpha reductase enzyme catalyzes testosterone's
conversion within the prostate to be the more potent androgen,
dihydrotestosterone (DHT), and this enzyme interacts with androgen receptors
(AR) to control average development. Therefore, the excessive production of DHT
in the prostate cause’s hyperplasia of prostate epithelial and prostate stromal
cells, contributing to BPH development in older men. Oxidative stress was
postulated as a critical essential factor for the production and progression of
BPH [28, 29,1], considering
the androgen imbalance. Testosterone-induced benign prostatic hyperplasia (BPH)
is related to the androgen receptor signaling pathway, to promote epithelial
cell proliferation; testosterone by the action of 5α reductase is converted
into dihydrotestosterone (DHT), this is a more potent androgen than
testosterone to stabilize and activate the transcriptional activity of the
androgen receptor (AR), thus significantly increasing tissue BPH compared to
the normal prostate, also increase PSA [1, 30, 29].
Androgens affect gene expression in various tissue and
cell types by binding to androgen receptors (AR), dihydrotestosterone (DHT) has
a higher affinity for AR than testosterone; in the prostate, the interaction
between DHT and AR induces the synthesis of proteins, such as prostate-specific
antigen (PSA). PSA, which is a glycoprotein in humans, is encoded by the
kallikrein-related peptide 3 (KLK3) gene and is secreted by prostatic
epithelial cells; when PSA rises in the blood, it is used as a clinical marker
for the prognosis of the disease. The hyperplasia of the stromal cells and the
prostatic epithelium would have as a mechanism an imbalance between cell
proliferation and death, favoring cell proliferation and inhibiting apoptosis [31]. Sinomenine hydrochloride (SIN) is the main bioactive
alkaloid isolated from the root of the traditional Chinese medicinal plant. In
BPH-1 cells, SIN therapy significantly decreased Bcl-2 protein expression,
significantly increased Bax protein expression, and significantly decreased
PCNA protein expression. These results indicate that SIN therapy inhibited the
proliferation of BPH-1 cells through the apoptotic pathway. SIN therapy
significantly reduced protein expression of Bcl-2 and PCNA in the PG tissues of
mice with TP-induced BPH in vivo, indicating that SIN treatment alleviated BPH
via the apoptotic pathway, which was consistent with in vitro data. These
findings suggest that SIN treatment may improve BPH via the apoptotic pathway [32, 33].
Inflammation is another mechanism for the development
of BPH, which is also an important clue. In about 90 percent of the samples
taken during transurethral resection of prostate BPH, histological evidence of
prostate inflammation is present. The metabolites of arachidonic acid (AA) are
generated by cyclooxygenase (COX) lipoxygenase (LOX), and cytochrome P450
monooxygenase (CYP450) pathways, respectively. They have been acknowledged to
play a crucial and essential role in inflammatory processes and BPH pathogenicity.
Many eicosanoid compounds derived from the COX and LOX pathways can determine
the degree of inflammation and pharmacological response as biomarkers related
to diseases in a biological system. This principle of action is also applicable
to the findings of the assessment of prostate gland measurements (Fig. 4) when the beneficial effect of the Gynerium
sagittatum (Caña Brava) methanol extract is assessed showing a decrease in
prostate gland length with an extract dose of 50 mg/kg, and there is also
evidence of a reduction in prostate gland length with a dose of 50 mg/kg [19, 20] (Fig. 6). The mechanisms of treatment of benign prostatic
hyperplasia)
4.
Conclusions
This experimental study allowed us to face a current
public health problem and make and use the effectiveness of the natural
resources that we have at our disposal, such as the Gynerium sagittatum
(Caña Brava) guide. Likewise,
given that the experiment had favorable results in rats it is important to
promote further research so that this treatment can be applied in humans, since
it is a highly accessible resource for the community. We can observe that a 99%
decrease in the comparative prostate index was observed in control group I, and
a better effect was observed at a dose of 500 mg/kg (P <0.004). This study
has shown that GS has a beneficial effect on induced benign prostatic
hyperplasia in rats.
Authors’ contributions
Al authors contributed
equally
Acknowledgements
To
the technician Mr. Madrid for the constant help in our project for the care of
the test animals.
Funding
No fund received for this study.
Availability of data and materials
All data are available
in the main text. Additional data will be
made available on request according to the journal policy.
Conflicts of interest
Authors declare no
competing interests.
References
1.
Langan, R.C.
Benign Prostatic Hyperplasia. Prim Care. 2019, 46(2), 223-232.
https://doi:10.1016/j.pop.2019.02.003.f
2.
Mejía, M.;
Miranda, J. Use and Advantages of the "International Prostate Symptoms
Scale" for management and follow-up with tamsulosin in benign prostatic
hyperplasia in Dr. Gustavo Dominguez Z. Hospital, Santo Domingo de Los
Tsáchilas (Undergraduate Thesis). 2016. Techn Univer of Manabí, Portoviejo,
Manabí, Ecuador.
3.
Barry, M.J.
Williford, W.O.; Fowler, F.J. Jr; Jones, K.M.; Lepor, H. Filling and voiding
symptoms in the American Urological Association symptom index: the value of
their distinction in a Veterans Affairs randomized trial of medical therapy in
men with a clinical diagnosis of benign prostatic hyperplasia. J Urol. 2000,
164(5),1559-1564. https://doi.org/10.1016/S0022-5347(05)67028-0.
4.
Prósper, M.;
Catalá, L.; Monedero, A.; Santamaría, J. Benign Prostatic Hyperplasia, Clinical
Action Guide in A. P, 2008. Clinical Hospital. Valencia- Urology Service, 1-19.
http://clinicomalvarrosa.san.gva.es/Accessed April 4, 2020
5.
Claus, G.;
Roehrborn, M.D.; FACS. Benign Prostatic Hyperplasia. An Rev in Urol, 2005: Vol.
7 Suppl 9. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1477638/Accessed April
6, 2020.
6.
Shoaib, S.M.;
Esmat, A.; Khalifa. A.E.; Abdel-Naim, A.B. Chrysin attenuates
testosterone-induced benign prostate hyperplasia in rats. Food Chem. Toxicol. 2018,
111, 650-659. https://doi:10.1016/j.fct.2017.12.017.
7.
Martínez, S.,
González, J.; Culebras, M. Flavonoids: antioxidant properties and actions. Hosp. Nutri. J. 2002, 6, 271-278.
8.
Elterman, D.;
Aubé-Peterkin, M.; Evans, H.; Elmansy, H.; Meskawi, M.; Zorn, K.C.; et al.
UPDATE - 2022 Canadian Urological Association guideline on male lower urinary
tract symptoms/benign prostatic hyperplasia (MLUTS/BPH). Can. Urol. Assoc. J.
2022, 16(8)
9.
Pajares, E.H.;
Bautista, F.B.; Florián, J.C.; Pérez, C.L. Extracto acuoso de la raíz de Gynerium sagittatum (Aublet) P. Beauv
“caña brava” y la inducción de hiperplasia prostática benigna en Rattus rattus
albinus. Pueblo Cont. 2011, 22(1),
181.
10.
Huarcaya, L.D. Efecto
beneficioso del extracto metanólico de Gynerium
sagittatum (caña brava) en la hiperplasia prostática benigna inducida por
testosterona en ratas en comparación con finasteride (Tesis de Maestría–Universidad
Nacional Mayor de San Marcos). 2022. https://cybertesis.unmsm.edu.pe/handle/20.500.12672/11662.
11.
Xie, J.; Qian, Y.Y.;
Yang, Y.; Peng, L.J.; Mao, J.Y.; Yang, M.R.; et al. Isothiocyanate from Moringa oleifera seeds inhibits the
growth and migration of renal cancer cells by regulating the PTP1B-dependent
Src/Ras/Raf/ERK signaling pathway. Front Cell Dev.
Biol. 2022, 9, 1–16.
12.
Yong-Bing, X.;
Gui-Lin, C.; Ming-Quan, G. Antioxidant and anti-inflammatory activities of the
crude extracts of Moringa oleifera
from Kenya and their correlations with flavonoids. Antioxidants.
2019, 8(8).
13.
Jaja-Chimedza, A.
Graf, B.L.; Simmler, C.; Kim, Y.; Kuhn, P.; Pauli, G.F.; et al. Biochemical
characterization and anti-inflammatory properties of an isothiocyanate-enriched
moringa (Moringa oleifera) seed
extract. PLoS One. 2017,12(8),1–21.
14.
Ugaz, L. Phytochemical
research. Second edition. Lima: Editorial Pontifical Fund Catholic University
of Peru. 1994, 2, 38-39.
https://www.worldcat.org/title/investigacion-fitoquimica-metodos-en-el-estudio-de-productos-naturales/oclc/1006393217
. Accessed March 26, 2020.
15.
Tona, L.; Kambu, K.; Ngimbi,
N.; Cimanga, K.; Vlietinck, A.J. Antiamoebic
and phytochemical screening of some Congolese medicinal plants. J.
Ethnopharm. 1998, 6, 57-65. https://doi.org/10.1016/S0378-8741(98)00015-4.
16.
Dominguez, A.
Methods of phytochemical research. Mexico: Limusa
Edition 2, 1993, 113-115.
https://books.google.com.pe/books?id=OgsHEAAAQBAJ&pg=PA182&lpg=PA182&dq=DOMINGUEZ+A,+Methods+of+Phytochemical+Research.+Mexico:+Limusa+Edition+2&source=bl&ots=0j7Q_nyg0o&sig=ACfU3U36R9m5-10etxIj1_vlkax7kw_eBg&hl=es&sa=X&ved=2ahUKEwiQlP2SndnvAhXyg-AKHZtPAOsQ6AEwBXoECAsQAw#v=onepage&q=DOMINGUEZ%20A%2C%20Methods%20of%20Phytochemical%20Research.%20Mexico%3A%20Limusa%20Edition%202&f=false.
Accessed March 25, 2020.
17.
Gonzales, G.F., Miranda,
S.; Nieto, J.; et al. Red maca
(Lepidium meyenii) reduced prostate size in rats. Reprod
Biol. Endocrinol. 2005, 3, 5. Published 2005 Jan 20. https://doi:10.1186/1477-7827-3-5
18.
Wang, R.; Kobayashi, Y.;
Lin, Y.; et al. A phytosterol
enriched refined extract of Brassica
campestris L. pollen significantly improved benign prostatic hyperplasia
(BPH) rat model compared to the classical TCM pollen preparation Qianlie Kang
Pule'an Tablets. Phytomedicine, 2015, 22(1), 145-152.
https://doi:10.1016/j.phymed.2014.10.001.
19.
Benavides, A.;
Bassarello, C.; Montoro, P.; Vilegas, W.; Piacente, S.; Pizza, C. Flavonoids
and isoflavonoids from Gynerium
Sagittatum. Phytochem. 2007, 68,1277-1284.
https://doi.org/10.1016/j.phytochem.2007.03.007.
20.
Zabaiou, N.;
Mabed, D.; Lobaccaro, J.; Lahouel, M. Oxidative stress in benign prostatic
hyperplasia. Androl, 2016, 48, 69-73.
https://doi.org/10.1111/and.12420.
21.
Buncharoen, W.;
Kanokporn, S.; Supap, S.; Chatchote, T. Uvaria
rufa Blume attenuates benign prostatic hyperplasia via inhibiting 5α-reductase and enhancing antioxidant status. J.
Ethnopharmacol. 2016, 1 -37. https://doi.org/10.1016/j.jep.2016.10.036.
22.
Park, E.; Lee, M.Y.;
Seo, C.S.; Jeon, W.Y.; Shin, H.K. Yongdamsagan-tang, a traditional herbal
formula, inhibits cell growth through the suppression of proliferation and
inflammation in benign prostatic hyperplasia epithelial-1 cells. J.
Ethnopharmacol. 2017, 20, 230-235. https://doi:10.1016/j.jep.2017.08.002
23.
Bjørklund, G.;
Dadar, M.; Chirumbolo, S.; Lysiuk, R. Flavonoids as detoxifying and
pro-survival agents: What is new? Food Chem.
Toxic, 2017, 1-40. https://doi.org/10.1016/j.fct.2017.10.039.
24.
Dai, G.C.; Hu, B.;
Zhang, W.F.; et al. Chemical characterization, antibenign prostatic hyperplasia
effect, and subchronic toxicity study of total flavonoid extract of Pteris multifida. Food
Chem. Toxicol. 2017,108 (Pt B), 524-531. https://doi:10.1016/j.fct.2016.11.010.
25.
Mbaka, G.;
Ogbonnia, S.; Sulaiman, A.; Osiagwu, D. Histomorphological effects of the oil
extract of Sphenocentrum jollyanum
seeds on benign prostatic hyperplasia induced by exogenous testosterone and
estradiol in adult Wistar rats. Avicenna J. Phytomed.
2019, 9(1), 21-33. https://doi.org/10.1016/j.ejbas.2016.11.003.
26.
Rosenberg, R.;
Jenkins, D.; Brown, T.; Diamandis, E. Flavonoids can block PSA production by
breast and prostate cancer cell lines. Clinica
Chim. Acta, 2002, 317
17–26. https://doi.org/10.1016/S0009-8981(01)00698-2.
27.
Deters, L.; Kim, E.; et
al. Benign Prostatic Hyperplasia (BPH). Medscape, 2017.
https://emedicine.medscape.com/article/437359- overview.
28.
Minutoli,
L.; Rinaldi, M.; Marini, H.; et al. Apoptotic
pathways linked to endocrine system as potential therapeutic targets for benign
prostatic hyperplasia. Int. J. Mol. Sci. 2016,17(8), 1311.
https://doi:10.3390/ijms17081311.
29.
Park, E.; Lee,
M.; Jeon, W.; Seo, C.; You, S.; Shin, H.; Paljung, S.A. Traditional herbal
medicine, attenuates benign prostatic hyperplasia In Vitro and In Vivo. J.
Ethnopharm. 2018, 1-34. https://doi.org/10.1016/j.jep.2018.02.037.
30.
Kusuma, D.G.W.; Sari, Y.A.;
Gde Oka, A.A.; Santosa, K.B.; Yudiana, I.W.; Wisnu, T.P.M.; et al. Serum testosterone and prostate-specific antigen
levels are major risk factors for prostatic volume increase among benign
prostatic hyperplasia patients. Asian J. Urol. 2021, 8(3), 289–97.
https://doi.org/10.1016/j.ajur.2020.06.001.
31.
Pistritto, G.;
Trisciuoglio, D.; Ceci, C.; Alessia, G.; D’Orazi, G. Apoptosis as anticancer
mechanism: Function and dysfunction of its modulators and targeted therapeutic
strategies. Aging (Albany NY). 2016, 8(4), 603–19.
32.
Fan, M.S.; Xia,
Y.F.; Ye, R.H.; Sun, Z.R.; Wang, M.Y.; An, M.F.; Zhang, S.S.; Zhang, L.J.; Zhao,
Y.L.; Xiang, Z.M.; Sheng, J. Sinomenine hydrochloride can ameliorate benign
prostatic hyperplasia by lowering the 5α-reductase 2 level and regulating the
balance between the proliferation and apoptosis of cells. Molecules.
2023,28(2), 803. Doi: 10.3390/molecules28020803. PMID: 36677863; PMCID:
PMC9867214.
33. Lee, H.; Moon, S.J.; Yoo, Y.D.; Jeong, E.J.; Rho, J.R.
Voratins A-C: pyridinium alkaloids from the marine dinoflagellate Effrenium voratum with inhibitory
effects on biomarkers for benign prostatic hyperplasia. J. Nat. Prod. 2022, 24,
85(6), 1495-1502. Doi: 10.1021/acs.jnatprod.1c01190. Epub 2022 Jun 7. PMID:
35671052.
This work is licensed under the
Creative Commons Attribution
4.0
License (CC BY-NC 4.0).
Abstract
Gynerium sagittatum (Caña Brava) is used in ethnomedicine to treat
benign prostatic hyperplasia without any scientific information on its safety
profile after its administration. Evaluate the possible curative effect of
methanolic extract of Gynerium sagittatum (GS) on testosterone-induced benign
prostatic hyperplasia in rats. 36 male rats with an average weight of 300 g ±
50 g and 2.5 months of age were used, 6 random groups of 6 rats each were
formed; Group I, blank: with physiological serum 2 mL / Kg every 24 h. for Per
Orally (PO), control group II: with olive oil subcutaneous 0.5 mL +
testosterone 25 mg (TA), group III: with olive oil subcutaneous 0.5 ml +
testosterone 25 mg + extract of Gynerium sagittatum 50 mg/kg PO, group
IV: olive oil subcutaneous 0.5 mL + testosterone 25 mg + extract of Gynerium
sagittatum 250 mg/kg, Group V: olive oil subcutaneous 0.5 mL + testosterone
25 mg + extract of Gynerium sagittatum 500 mg/kg, Group VI: olive oil
subcutaneous 0.5 mL + testosterone 25 mg + Finasteride 0.6 mg/kg. weighed
subsequent treatments, and prostate, kidneys, and liver were measured, and a
pathological study determined prostate-specific antigen and serum determination of toxicity markers
by liver profile. A 99% decrease in the comparative prostate index was observed
in control group I, and a better effect was observed at a dose of 500 mg/kg (P
<0.004). This study has shown that GS has a beneficial effect on induced
benign prostatic hyperplasia in rats.
Abstract Keywords
Prostate, specific
antigen toxicity, flavonoids, Gynerium sagittatum.
This work is licensed under the
Creative Commons Attribution
4.0
License (CC BY-NC 4.0).
Editor-in-Chief
Prof. Dr. Radosław Kowalski
This work is licensed under the
Creative Commons Attribution 4.0
License.(CC BY-NC 4.0).